Intensity Therapeutics, Inc. (INTS) revenue by segment
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.08−0.02 (-0.65%)
Close on Nov 13, 2026Market cap $10.06MP/E –Yield –
Intensity Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Intensity Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to Intensity Therapeutics's operating metrics, with full history, charts and a link to each filing.
See a number that looks wrong?